Opportunity ID: 337526

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-HL-23-012
Funding Opportunity Title: Catalyze: Product Definition for Small Molecules and Biologics – Preliminary Product/Lead Series Identification (R33 – Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.233 — National Center on Sleep Disorders Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 2
Posted Date: Jan 24, 2022
Last Updated Date: Nov 22, 2024
Original Closing Date for Applications: Dec 20, 2024
Current Closing Date for Applications: Nov 21, 2024
Archive Date: Dec 21, 2024
Estimated Total Program Funding:
Award Ceiling: $350,000
Award Floor:

Eligibility

Eligible Applicants: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal governments (Federally recognized)
For profit organizations other than small businesses
Independent school districts
Small businesses
County governments
Public housing authorities/Indian housing authorities
Public and State controlled institutions of higher education
City or township governments
Native American tribal organizations (other than Federally recognized tribal governments)
State governments
Private institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name: National Institutes of Health
Description:

This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.

Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-012.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster

OERWebmaster03@od.nih.gov
Email:OERWebmaster03@od.nih.gov

Version History

Version Modification Description Updated Date
Update close date per reissued NOFO RFA-HL-26-018. Nov 22, 2024
Jan 24, 2022

DISPLAYING: Synopsis 2

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-HL-23-012
Funding Opportunity Title: Catalyze: Product Definition for Small Molecules and Biologics – Preliminary Product/Lead Series Identification (R33 – Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.233 — National Center on Sleep Disorders Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 2
Posted Date: Jan 24, 2022
Last Updated Date: Nov 22, 2024
Original Closing Date for Applications: Dec 20, 2024
Current Closing Date for Applications: Nov 21, 2024
Archive Date: Dec 21, 2024
Estimated Total Program Funding:
Award Ceiling: $350,000
Award Floor:

Eligibility

Eligible Applicants: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal governments (Federally recognized)
For profit organizations other than small businesses
Independent school districts
Small businesses
County governments
Public housing authorities/Indian housing authorities
Public and State controlled institutions of higher education
City or township governments
Native American tribal organizations (other than Federally recognized tribal governments)
State governments
Private institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name: National Institutes of Health
Description:

This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.

Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-012.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster

OERWebmaster03@od.nih.gov
Email:OERWebmaster03@od.nih.gov

DISPLAYING: Synopsis 1

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-HL-23-012
Funding Opportunity Title: Catalyze: Product Definition for Small Molecules and Biologics – Preliminary Product/Lead Series Identification (R33 – Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.233 — National Center on Sleep Disorders Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Jan 24, 2022
Last Updated Date: Jan 24, 2022
Original Closing Date for Applications:
Current Closing Date for Applications: Dec 20, 2024
Archive Date: Jan 25, 2025
Estimated Total Program Funding:
Award Ceiling: $350,000
Award Floor:

Eligibility

Eligible Applicants: Others (see text field entitled “Additional Information on Eligibility” for clarification)
County governments
Independent school districts
Public housing authorities/Indian housing authorities
Private institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
City or township governments
For profit organizations other than small businesses
Small businesses
State governments
Native American tribal organizations (other than Federally recognized tribal governments)
Special district governments
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name: National Institutes of Health
Description: This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-012.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
OERWebmaster03@od.nih.gov
Email:OERWebmaster03@od.nih.gov

Folder 337526 Full Announcement-RFA-HL-23-012 -> RFA-HL-23-012-Full-Announcement.pdf

Packages

Agency Contact Information: NIH OER Webmaster
OERWebmaster03@od.nih.gov
Email: OERWebmaster03@od.nih.gov
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-G Use for due dates on or before January 24, 2023 PKG00271515 Feb 21, 2022 Jan 24, 2023 View
FORMS-H Use for due dates on or after January 25, 2023 PKG00278290 Nov 10, 2022 Nov 23, 2024 View

Package 1

Mandatory forms

337526 RR_SF424_5_0-5.0.pdf

337526 PHS398_CoverPageSupplement_5_0-5.0.pdf

337526 RR_OtherProjectInfo_1_4-1.4.pdf

337526 PerformanceSite_4_0-4.0.pdf

337526 RR_KeyPersonExpanded_4_0-4.0.pdf

337526 RR_Budget_3_0-3.0.pdf

337526 PHS398_ResearchPlan_4_0-4.0.pdf

337526 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

337526 RR_SubawardBudget30_3_0-3.0.pdf

337526 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 2

Mandatory forms

337526 RR_SF424_5_0-5.0.pdf

337526 PHS398_CoverPageSupplement_5_0-5.0.pdf

337526 RR_OtherProjectInfo_1_4-1.4.pdf

337526 PerformanceSite_4_0-4.0.pdf

337526 RR_KeyPersonExpanded_4_0-4.0.pdf

337526 RR_Budget_3_0-3.0.pdf

337526 PHS398_ResearchPlan_5_0-5.0.pdf

337526 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

337526 RR_SubawardBudget30_3_0-3.0.pdf

337526 PHS_AssignmentRequestForm_3_0-3.0.pdf

2025-07-12T10:51:14-05:00

Share This Post, Choose Your Platform!

About the Author: